Syncona Ltd to acquire all shares of Freeline Therapeutics at the rate of $6.5/share

LONDON, UK: Syncona Ltd’s newly established portfolio company has entered into an agreement with Freeline Therapeutics Holdings plc to acquire all of the shares of Freeline that Syncona does not currently own in an all-cash transaction. Syncona currently owns 49.7% of Freeline. Under the agreement, a newly established Syncona portfolio company will acquire Freeline for…

Syncona offers $5.00 per share to take full control of Freeline Therapeutics

LONDON, UK: Syncona, a healthcare company that creates, builds and scales global leaders in life science, has made a non-binding offer to buy the rest of Freeline Therapeutics, a gene therapy company that Syncona co-founded in 2015. Syncona already owns about 57.9% of Freeline’s shares and wants to pay $5.00 in cash for each American…